2020
DOI: 10.1186/s12933-019-0977-z
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: Background: Few prospective studies have compared the cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase 4 (DPP-4) inhibitors. We aimed to clarify the efficacy of dapagliflozin versus sitagliptin for modulating cardiometabolic risk factors including high glycated hemoglobin (HbA1c) levels, hypoglycemia, and body weight. Methods: This prospective, randomized, open-label, blinded-endpoint, parallel-group trial enrolled 340 Japanese patients with early-stage type… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

10
97
1

Year Published

2020
2020
2020
2020

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 92 publications
(108 citation statements)
references
References 49 publications
(64 reference statements)
10
97
1
Order By: Relevance
“…In animal or human studies, SGLT2i have been reported to have many benefits for vasculature, such as improved endothelial function, vasodilatation, and attenuated oxidative stress, suggesting that SGLT2i may be able to halt the progression of atherosclerosis and improve vascular outcomes [ 34 36 ]. In addition, SGLT2i had been reported to improve cardiometabolic risk factors than DDP4i [ 37 ]. PAD is a manifestation of systemic atherosclerosis, and because SGLT2i could reduce the risk of adverse atherosclerotic events, it may also be beneficial in reducing the risk of adverse limb events for patients with PAD [ 23 , 38 , 39 ].…”
Section: Discussionmentioning
confidence: 99%
“…In animal or human studies, SGLT2i have been reported to have many benefits for vasculature, such as improved endothelial function, vasodilatation, and attenuated oxidative stress, suggesting that SGLT2i may be able to halt the progression of atherosclerosis and improve vascular outcomes [ 34 36 ]. In addition, SGLT2i had been reported to improve cardiometabolic risk factors than DDP4i [ 37 ]. PAD is a manifestation of systemic atherosclerosis, and because SGLT2i could reduce the risk of adverse atherosclerotic events, it may also be beneficial in reducing the risk of adverse limb events for patients with PAD [ 23 , 38 , 39 ].…”
Section: Discussionmentioning
confidence: 99%
“…Of note, it is very important to evaluate the effects of anti-diabetic agents on GV, and their potential to attenuate the progression of coronary atherosclerosis [ 50 , 51 ]. Recent evidence has indicated that DPP-4 inhibitors can improve GV and stabilize coronary artery plaques to a degree greater than that of usual medical care [ 52 , 53 ]. Other emerging therapeutic agents, such as SGLT2 inhibitors, have also been shown to effectively reduce glucose fluctuations [ 54 ].…”
Section: Discussionmentioning
confidence: 99%
“…Also, our data from the linear mixed-effects model showed a rapid BG drop during hemodialysis and a tendency for hypoglycemia in the subsequent nighttime period in maintenance hemodialysis patients with type 2 diabetes. Although DPP-4 inhibitors have been shown to improve BG variability in patients with type 2 diabetes in many randomized controlled trials (RCTs) [41][42][43][44][45][46][47][48][49] (see the table in the Electronic supplementary material), few studies have reported the same effect in maintenance hemodialysis patients [50]. Our study illustrates the usefulness of DPP-4 inhibitors in these patients.…”
Section: Discussionmentioning
confidence: 55%
“…The ability of DPP-4 inhibitors to suppress BG variability in patients with type 2 diabetes has been shown in studies using CGM [51, 52]. Furthermore, several RCTs using CGM found that BG variability is suppressed more effectively by DPP-4 inhibitors than by other agents such as sulfonylureas [41,42] and sodium glucose cotransporter 2 inhibitors [43][44][45] [41,49], or had used metformin only [41][42][43]46]. There have also been some reports on the usefulness of DPP-4 inhibitors in patients on hemodialysis [50], but none has shown obvious suppression of BG variability.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation